Registered title, quoted from ClinicalTrials.gov
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07748325, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed non-small cell lung cancer.
Inclusion criterion 2
Pathologic lymph-node involvement;
Inclusion criterion 5
Postoperative pathologic T2 or higher disease;
Inclusion criterion 6
Failure to achieve a major pathologic response, defined as more than 10% residual viable tumor cells in the primary tumor;
Inclusion criterion 7
High-risk histologic components, including solid, micropapillary, or adenosquamous components;
Inclusion criterion 10
Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and must agree to use effective contraception during the study and for 3 months after the last dose of study treatment. Male participants with partners of childbearing potential must agree to use effective contraception during the study and for 8 weeks after the last dose.
Inclusion criterion 23
Eastern Cooperative Oncology Group performance status of 0 or 1.
Inclusion criterion 13
Hemoglobin of at least 90 g/L;
Inclusion criterion 15
Absolute neutrophil count of at least 1.5 × 10\^9/L;
Inclusion criterion 16
Platelet count of at least 75 × 10\^9/L;
Inclusion criterion 17
Total bilirubin no greater than 1.5 times the upper limit of normal;
Inclusion criterion 18
Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 60 mL/min;
Inclusion criterion 20
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07748325, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female participants aged 18 to 75 years.
- Histologically or cytologically confirmed non-small cell lung cancer.
- Completion of 2 to 4 cycles of neoadjuvant immune checkpoint inhibitor therapy combined with chemotherapy, followed by complete (R0) surgical resection.
- At least one of the following protocol-defined high-risk features for postoperative recurrence:
- Pathologic lymph-node involvement;
- Postoperative pathologic T2 or higher disease;
- Failure to achieve a major pathologic response, defined as more than 10% residual viable tumor cells in the primary tumor;
- Pleural invasion;
- Intravascular tumor emboli;
- High-risk histologic components, including solid, micropapillary, or adenosquamous components;
- Detectable molecular residual disease.
- For participants with lung adenocarcinoma, absence of sensitizing EGFR mutations and ALK rearrangements. Molecular testing is not mandatory for participants with squamous cell carcinoma according to the current protocol.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Adequate organ function within 7 days before randomization, as demonstrated by all of the following:
- Hemoglobin of at least 90 g/L;
- Absolute neutrophil count of at least 1.5 × 10\^9/L;
- Platelet count of at least 75 × 10\^9/L;
- Total bilirubin no greater than 1.5 times the upper limit of normal;
- Alanine aminotransferase and aspartate aminotransferase no greater than 2.5 times the upper limit of normal;
- Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 60 mL/min;
- Left ventricular ejection fraction of at least 50%;
- International normalized ratio or prothrombin time no greater than 1.5 times the upper limit of normal.
- Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and must agree to use effective contraception during the study and for 3 months after the last dose of study treatment. Male participants with partners of childbearing potential must agree to use effective contraception during the study and for 8 weeks after the last dose.
- Ability to understand the study requirements, willingness to provide written informed consent, and ability to comply with study treatment and follow-up procedures.
Exclusion Criteria:
- Small cell lung cancer or non-small cell lung cancer containing a small cell carcinoma component.
- Incomplete resection, including R1 or R2 resection, or salvage surgery.
- Clinically significant malnutrition as determined by the investigator.
- A history of clinically significant immune-related adverse events during prior treatment, including grade 3 or higher immune-mediated pneumonitis, myocarditis, or another serious immune-related adverse event that, in the investigator's judgment, makes further immune checkpoint inhibitor therapy unsafe.
- Signs, symptoms, or a known history of clinically significant interstitial lung disease.
- Any severe or uncontrolled concurrent medical condition, including:
- Inadequately controlled hypertension;
- Grade 2 or higher myocardial ischemia, myocardial infarction, clinically significant arrhythmia, corrected QT interval of at least 480 milliseconds, or New York Heart Association class II or higher heart failure;
- Active or uncontrolled infection of grade 2 or higher;
- Decompensated liver disease, active hepatitis, or chronic viral hepatitis requiring antiviral therapy;
- Renal failure requiring hemodialysis or peritoneal dialysis;
- Known human immunodeficiency virus infection, another acquired or congenital immunodeficiency disorder, or a history of organ transplantation;
- Poorly controlled diabetes mellitus, defined as fasting blood glucose greater than 10 mmol/L;
- Urine protein of 2+ or greater with a 24-hour urinary protein level greater than 1.0 g;
- Clinically significant coagulation abnormalities or an increased risk of bleeding;
- A seizure disorder requiring treatment.
- A concurrent active malignancy, except for malignancies specifically permitted by the final protocol.
- An active autoimmune disease or another immune-mediated disease requiring systemic treatment.
- Long-term treatment with systemic immunosuppressive therapy or systemic corticosteroids, except for protocol-permitted physiologic replacement therapy.
- An active psychiatric disorder, cognitive impairment, or another condition that would prevent provision of informed consent or adherence to study treatment and follow-up.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07748325, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07748325, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.